{"id":437663,"date":"2023-02-22T11:34:59","date_gmt":"2023-02-22T10:34:59","guid":{"rendered":"https:\/\/innovationorigins.com\/?p=437663"},"modified":"2023-02-22T11:34:59","modified_gmt":"2023-02-22T10:34:59","slug":"another-major-investment-round-for-xeltis-e32-million-for-the-development-of-restorative-cardiovascular-devices","status":"publish","type":"post","link":"https:\/\/ioplus.nl\/archive\/en\/another-major-investment-round-for-xeltis-e32-million-for-the-development-of-restorative-cardiovascular-devices\/","title":{"rendered":"Another major investment round for Xeltis: \u20ac32 million for the development of restorative cardiovascular devices"},"content":{"rendered":"\n

Xeltis<\/a>, a clinical stage medtech company developing living implants that enable the body to restore cardiovascular function, has raised \u20ac32 million in a Series D2 equity fundraise. The fundraising has been backed by a syndicate of current and new investors, including Grand Pharma, DaVita Venture Group, EQT Life Sciences, Invest-NL, and other international investors. This fundraising round will enable Xeltis to progress its key clinical programs into pivotal trials, as it aims to give patients around the world access to the world\u2019s most advanced restorative cardiovascular devices.<\/p>\n\n\n\n

In 2017, Xeltis was one of the winners of Innovation Origins’ Gerard & Anton Awards<\/a>.<\/p>\n\n\n\n

Xeltis\u2019 breakthrough technology is focused on restoring the body\u2019s natural cardiovascular functions, with numerous potential applications. The Company\u2019s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer-based material that triggers the body\u2019s natural healing response to regenerate the patient\u2019s own tissue around it, forming new, living, and long-lasting vessels and valves.
Xeltis\u2019 most advanced program, aXess, is a vascular access graft for patients with chronic kidney disease (CKD) requiring hemodialysis. Preliminary in-human clinical trial data from the Company\u2019s ongoing aXess studies have been very encouraging. The Company is also pursuing clinical programs in pulmonary valve replacement and coronary artery bypass grafts.<\/p>\n\n\n\n

China<\/h2>\n\n\n\n

Alongside the equity fundraise, Xeltis and Grand Pharma<\/a> have completed a license deal, covering Greater China, for aXess and other potential hemodialysis products developed under the same technology platform. Under the agreement, Grand Pharma will have exclusive rights to develop, produce and commercialize these products in Greater China.<\/p>\n\n\n

<\/a>
<\/div><\/div>
Much more on Xeltis’ development<\/div>
Read everything we published on this company in the past years.<\/div><\/div><\/div>\n\n\n

\u201cThe strategic support of Grand Pharma and DaVita alongside our existing investor base represents a strong validation of our technology and potential to transform the landscape of cardiovascular surgery. We remain focused on progressing our aXess clinical trials, as well as exploring our next steps in other indications,\u201d\u00a0commented Eliane Schutte, CEO of Xeltis.<\/strong>\u00a0\u201cSecuring this financing is an important milestone for Xeltis. We are proud to have attracted such high-profile investors to our company and look forward to leveraging their respective insights \u2013 from clinical expertise to the product development lifecycle \u2013 as we continue on the next phase of growth.\u201d<\/p>\n\n\n\n

Frank Zhou, Grand Pharmaceutical Group CEO, added:<\/strong>\u00a0\u201cXeltis is leading the way in addressing the current limitations of access grafts for hemodialysis patients, using a ground-breaking approach based on its world-leading ETR platform. We believe the company\u2019s technology has enormous potential to benefit patients and hospital care systems globally.\u201d<\/p>\n\n\n\n

Invest-NL<\/h2>\n\n\n\n

For Invest-NL, the investment in Xeltis fits well with its strategic focus to keep healthcare in the Netherlands accessible and affordable. “Xeltis’ innovative products help improve both the quality of treatment and the quality of life for patients,” said CEO Rinke Zonneveld. “By preventing common complications, significant savings in healthcare costs in the Netherlands are also expected.”<\/p>\n\n\n\n

To determine the social benefits of the investment in Xeltis, Invest-NL examined how many healthcare costs the innovation might prevent on the Dutch market and to whom those savings accrue: patient, healthcare provider, or healthcare insurer. It also calculated how many healthy life years the innovation would provide. “By looking at our investments in healthcare from an impact perspective, we take the fundability of healthcare innovations to the next level,” said Zonneveld.<\/p>\n","protected":false},"excerpt":{"rendered":"

Xeltis, a clinical stage medtech company developing living implants that enable the body to restore cardiovascular function, has raised \u20ac32 million in a Series D2 equity fundraise. The fundraising has been backed by a syndicate of current and new investors, including Grand Pharma, DaVita Venture Group, EQT Life Sciences, Invest-NL, and other international investors. This […]<\/p>\n","protected":false},"author":1568,"featured_media":521793,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[34665],"tags":[8098,45972,10413],"location":[6763],"article_type":[36684],"serie":[],"archives":[],"internal_archives":[],"reboot-archive":[],"class_list":["post-437663","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-china-en","tag-invest-nl-en","tag-xeltis","location-netherlands","article_type-news"],"blocksy_meta":[],"acf":{"subtitle":"\"Xeltis' innovative products help improve the quality of treatment and quality of life for patients.\"","text_display_homepage":false},"author_meta":{"display_name":"Bart Brouwers","author_link":"https:\/\/ioplus.nl\/archive\/author\/brewbart\/"},"featured_img":"https:\/\/ioplus.nl\/archive\/wp-content\/uploads\/2017\/04\/Screen-Shot-2017-04-22-at-13.26.08-300x146.png","coauthors":[],"tax_additional":{"categories":{"linked":["Health<\/a>"],"unlinked":["Health<\/span>"]},"tags":{"linked":["china<\/a>","Invest-NL<\/a>","Xeltis<\/a>"],"unlinked":["china<\/span>","Invest-NL<\/span>","Xeltis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on February 22, 2023","modified":"Updated on February 22, 2023"},"absolute_dates_time":{"created":"Posted on February 22, 2023 11:34 am","modified":"Updated on February 22, 2023 11:34 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/437663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/users\/1568"}],"replies":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/comments?post=437663"}],"version-history":[{"count":0,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/437663\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media\/521793"}],"wp:attachment":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media?parent=437663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/categories?post=437663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/tags?post=437663"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/location?post=437663"},{"taxonomy":"article_type","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/article_type?post=437663"},{"taxonomy":"serie","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/serie?post=437663"},{"taxonomy":"archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/archives?post=437663"},{"taxonomy":"internal_archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/internal_archives?post=437663"},{"taxonomy":"reboot-archive","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/reboot-archive?post=437663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}